undefined undefined
NaN.000
NaN.00%
Ratings for Mersana Therapeutics (NASDAQ:MRSN) were provided by 5 analysts in t...
03-01 00:00
Mersana Therapeutics (NASDAQ:MRSN) reported quarterly losses of $(0.16) per share which met the analyst consensus estimate. This is a 63.64 percent increase over losses of $(0.44) per share from the same period last
02-28 20:02
Companies Reporting Before The Bell • ICL Group (NYSE:ICL) is likely to report quarterly earnings at $0.08 per share on revenue of $1.69 billion.
02-28 19:24
Mersana Therapeutics, Inc. (NASDAQ:MRSN) shares have continued their recent mom...
02-23 03:39
Shares of KeyCorp (NYSE: KEY) moved lower during Thursday’s session after the company reported fourth-quarter financial results. Revenues of $1.538 billion, down 19.0% Y/Y, slightly topped the consensus of $1.532 billion. Adjusted EPS of 25 cents topped the street view of 23 cents.
01-19 02:08
瞻博网络大涨21.8%,获慧与科技140亿美元收购;Sarepta治疗隔夜涨16.7%,公司预计2023年全年收入为11.5亿美元>>
01-10 19:51
Enrollment in dose escalation and backfill cohorts continuing in Phase 1 clinical trial of XMT-1660, Dolasynthen B7-H4 ADC; expect to initiate expansion in Q2 2024 and announce initial clinical data in
01-05 21:28
Despite an already strong run, Mersana Therapeutics, Inc. (NASDAQ:MRSN) shares ...
2023-12-20 08:29
Citigroup analyst Ashiq Mubarack upgrades Mersana Therapeutics (NASDAQ:MRSN) from Neutral to Buy and raises the price target from $1 to $5.
2023-12-05 00:16